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urgent abdominal surgery. METHODS: Seventy abdominal sur-
geons from 20 Moscow hospitals were randomly selected for a
structured interview. The interviewing was carried out from May
to July 2007. Forty-four of them had previous experience with
use of the thrombin and ﬁbrinogen coated collagen patch, 26 of
them were without such experience. Using a Visual Analogue
Scale (VAS), the experts ﬁrst evaluated their satisfaction with
different haemostatic practices. Then they assessed the relative
hospital resource use and outcome consequences of the collagen
patch compared with alternative haemostasis management tech-
niques. These assessments were subsequently valued in a budget
impact model using Moscow hospital cost estimates and a
univariate sensitivity analysis was applied. RESULTS: As to the
surgeons’ satisfaction, the patch application got the highest score
of the different haemostatic techniques in all types of surgeries.
As to resource use, the patch resulted in a incremental reduction
in the following resource components: mean operating time in all
surgery types: 24 min per patient (liver—36 min, herniotomy—
25 min, intestine—24 min, stomach—23 min, pancreas—
21 min, gall-bladder—18 min), post-operative total hospital
stay: 3 days, including 1.3 ICU days, and use of transfused blood
200 ml (min—98 ml, max—287 ml). Also, complication rates
were reduced incrementally: internal hemorrhages by 12.45%;
suture failure by 6.63%; infectious complications by 4.9%. The
mean cost savings following the use of the patch compared to
alternative haemostatic agents in all types of surgeries were
RUR3637 (€103.6 for July 2007). CONCLUSIONS: According
to assessment by surgical experts, the application of a thrombin
and ﬁbrinogen coated collaged patch in abdominal surgery
potentially leads to reduction of post-operative complications,
reduction of surgery time, ICU and hospital stay in the Moscow
hospital setting. Finally it is likely to save net costs in all types of
abdominal surgeries.
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OBJECTIVES: MIS THA techniques have shown treatment
advantages over conventional THA—particularly in terms of
reduced hospital stay and rehabilitation time—key issues inﬂu-
encing the costs of THA. However, relatively few economic
studies have been conducted in this area. METHODS: Cost data
from 224 patients, 140 undergoing MIS hip procedures and
84 undergoing conventional THA in two German orthopaedic
centres were analyzed. Actual costs associated with MIS and
conventional THA were compared, including staff, hospital over-
heads and general costs. Differences in costs of prosthetic hip
implants were identiﬁed as a potential source of bias and were
therefore excluded from calculations. Comparisons across 12
quality indicators were made between THAs conducted in one
German hospital with the MIS technique, and the overall
German average from 2006 (published by the German Federal
Ofﬁce of Quality Assurance [BQS]). RESULTS: MIS technique
was associated with 28.5% lower total costs than conventional
THA. Cost savings were predominantly due to shorter duration
of hospital stay, shorter operation time, shorter post-operative
care, and associated lower costs for nurses, physiotherapists and
overheads. The two patient populations in the cost analysis had
similar baseline demographics. Regression analyses showed
that 84% of the difference between the two samples was an effect
of surgical technique; 16% might be caused by age and gender
(R2 = 0.67). Level of experience of surgeons was also identiﬁed
as a possible bias but no variance was observed. Quality com-
parison of the MIS technique in the hospital performing MIS
THA with overall data from the whole of Germany showed that
10 to 12 quality indicators favoured the MIS technique. There
were no post-operative wound infections in any of the MIS THA
procedures. CONCLUSIONS: This recent German cost compari-
son study demonstrates the treatment and economic advantages
provided by the range of MIS techniques over conventional
THA.
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OBJECTIVES: To assess efﬁcacy, safety and cost-effectiveness of
ultrasonic dissector, Harmonic Scalpel (HS) versus conventional
non video-assisted thyroidectomy (nHS), from hospital and soci-
etal perspectives. METHODS: A total of 198 patients eligible for
total thyroidectomy (TT) were randomly assigned to surgery
with HS(96) or nHS(102) and followed until 3 months after
discharge. Main clinical outcomes were: pain (VAS score), QoL
(EQ-5D), complications, cosmetic results. Direct medical and
indirect costs were prospectively collected as well. RESULTS: HS
led to shorter operative time (HS:54.16 vs nHS:76.36 minutes,
P < 0.001), as total operative room (OR) occupation time (76.86
vs 100.59 minutes, P < 0.001). QoL was better in HS-group one
month (0.90 vs 0.83 ; P < 0.002), and 3 months after surgery
(0.91 vs 0.84; P = 0,002). Less postoperative pain was perceived
by HS patients 6 hour after surgery (HS: 41.35 vs nHS: 44.56)
but similar after 48 hours (HS: 22.75 vs nHS:20.97). A total of
71% HS patients were satisﬁed with cosmetic result versus 55%
nHS (P = 0.029). No signiﬁcant difference resulted in complica-
tions rate and voice changes. Total medical direct costs were
€2400.34 and €2540.52 for HS and nHS, respectively. From
hospital perspective HS offers a cost saving of € 119/patient,
mainly due to less charges of OR personnel (HS: €294.19 vs nHS:
€452.90), OR occupancy (HS: €620.61 vs nHS: €815.40),
drugs (HS: €63.29 vs nHS: €93.28), and diagnostic exams (HS:
€132.91 vs nHS: €160.36). No statistical difference was found in
loss of productivity up to 3 months (HS: €385.51 vs nHS:
€377.71). CONCLUSIONS: Harmonic is safe and efﬁcacious in
conventional TT, allowing a signiﬁcant reduction of the operative
time (-22 min), total OR occupation time (-24 min), and better
QALY at 3 months (HS:0,23 vs nHS:0,21), without increasing
complications rate and saving €119 from a hospital perspective.
Harmonic should be adopted in TT to reduce impact on indi-
vidual life and on society.
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OBJECTIVES: Chronic low-back pain related to osteoarthritic
changes of the lumbar spine has a signiﬁcant economic impact on
health care budgets worldwide. Anterior-Lumbar-Interbody-
Fusion (ALIF) surgery can be an effective treatment option after
non-operative therapy fails. Frequently, the affected vertebrae are
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fused together using bone (autograft) from patient’s hip, which
requires additional surgery and leads to increased co-morbidity,
blood loss, infection rate, and pelvic instability. We assessed the
cost-effectiveness of rhBMP-2 compared with autograft in spine
fusion surgery over two years from both a health care payer’s and
societal perspectives in The Netherlands. METHODS: An eco-
nomic model was developed to evaluate differences in results
between spine-fusion surgery with rhBMP-2 and fusion with
bone autograft. The cost and health-related quality-of-life asso-
ciated with both treatment options were estimated for two years
after surgery. Data were obtained from a previously published
analysis of pooled data, in which patients in the rhBMP-2 arm
showed signiﬁcant clinical improvements after surgery compared
to standard therapy. Costs were obtained according to the Dutch
costing manual, and are reported in 2007 values. RESULTS: In
The Netherlands, from the health care payer’s perspective, using
rhBMP-2 lead to extra cost of €1,520 per case, and incremental
cost-effectiveness ratio (ICER) of €27,260/QALY. Signiﬁcant
reduction in secondary interventions, and better fusion rates
associated with rhBMP-2 treatment resulted in faster return to
work and reduced productivity loss. CONCLUSIONS: The stan-
dard use of rhBMP-2 in ALIF surgery is a cost-effective treatment
option in The Netherlands from the payer’s perspective, and a
cost-saving option from the societal perspective.
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OBJECTIVES: Assess cost-effectiveness of 35 days rivaroxaban,
an oral direct Factor Xa inhibitor, versus subcutaneous enox-
aparin regimens for prevention of venous thromboembolism
(VTE) following total hip replacement (THR). METHODS:
Rivaroxaban regimens were compared with enoxaparin regimens
following THR in two large randomized controlled trials. In
RECORD1, patients received 35 days prophylaxis with rivaroxa-
ban or enoxaparin. In RECORD2, patients received 35 days
rivaroxaban or 12 days enoxaparin. In RECORD1, rivaroxaban
reduced total VTE (composite: any DVT, non-fatal PE, all-cause
mortality) by 70% versus enoxaparin after 35 days prophylaxis,
although the reduction in symptomatic VTE was not statistically
signiﬁcant. In RECORD2, 35 days rivaroxaban reduced total
VTE by 79% and symptomatic VTE by 80% versus 12 days
enoxaparin. A cost–utility model (health care perspective),
populated by the RECORD1-2 trials, assessed cost-effectiveness
of rivaroxaban versus both durations of enoxaparin over ﬁve
years. Risks of VTE and post-thrombotic syndrome beyond the
trial period were estimated from published data. Costs, in euros
(€), were derived from published Spanish sources. Utilities were
derived from published literature. Enoxaparin prophylaxis after
THR in Spain lasts approximately 27 days. Hence, in addition to
separate analyses based on RECORD1 and 2, RECORD1-2 data
were pooled to allow the cost-effectiveness of 35 days rivaroxa-
ban versus the Spanish enoxaparin duration to be estimated.
RESULTS: Thirty-ﬁve days rivaroxaban dominated 35 days
enoxaparin, with a small QALY gain and cost savings of €48.10
per patient. Rivaroxaban,was also cost-effective versus 12 days
enoxaparin (incremental cost per QALY, €3156). Rivaroxaban
remained dominant over enoxaparin when RECORD1-2 data
were combined (QALY gain, 0.011; cost savings per patient,
€12.24). Probabilistic sensitivity analyses showed rivaroxaban
dominating in 60% of cases and cost-effective in 100% (cost per
QALY; €20,000) CONCLUSIONS: Rivaroxaban is cost-
effective versus both 12 days and 35 days enoxaparin, for pre-
venting VTE following THR in Spain.
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OBJECTIVES: Assess cost-effectiveness of 35 days rivaroxaban,
an oral direct Factor Xa inhibitor, versus 12 days and 35 days
subcutaneous enoxaparin for prevention of venous throm-
boembolism (VTE) following total hip replacement (THR).
METHODS: Rivaroxaban regimens were compared with
enoxaparin regimens following THR in two large randomized
controlled trials. In RECORD1, patients received 35 days
prophylaxis with rivaroxaban or enoxaparin. In RECORD2,
patients received 35 days rivaroxaban or 12 days enoxaparin.
The duration of enoxaparin in RECORD1 represents the ACCP-
recommended duration of prophylaxis following THR, but in
Canada a shorter duration is often applied. In RECORD1, rivar-
oxaban reduced total VTE (composite: any DVT, non-fatal PE,
all-cause mortality) by 70% versus enoxaparin after 35 days
prophylaxis. The reduction in symptomatic VTE with rivaroxa-
ban was not statistically signiﬁcant and not included in the
model. In RECORD2, rivaroxaban reduced total VTE by 79%
and symptomatic VTE by 80% versus 12 days enoxaparin. A
cost–utility model (Ministry of Health perspective) assessed cost-
effectiveness of rivaroxaban versus both durations of enoxaparin
over ﬁve years. The model is populated by RECORD1-2 trials,
while published epidemiological and clinical data estimated the
risk of further VTE events and post-thrombotic syndrome
beyond the trial period. Costs were derived from published
Canadian sources and expressed in 2008 Canadian Dollars (C$).
Utilities were derived from published literature. Potential savings
from oral administration were also included. RESULTS: Thirty-
ﬁve days rivaroxaban dominated 35 days enoxaparin, with a
small QALY gain and savings of C$282.58 per patient. Cost
savings are driven mainly by reduced outpatient administration
costs. Probabilistic sensitivity analyses showed this dominance in
98% of cases. Rivaroxaban was also cost-effective versus 12 days
enoxaparin, with an incremental cost per QALY of C$33,323.
CONCLUSIONS: Rivaroxaban is cost-effective versus both 12
days and 35 days enoxaparin, for the prevention of VTE follow-
ing THA in Canada.
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OBJECTIVES: Assess cost-effectiveness of rivaroxaban, an oral
direct Factor Xa inhibitor, versus subcutaneous enoxaparin for
prevention of venous thromboembolism (VTE) following total
knee replacement (TKR) in the UK and Spain. METHODS:
RECORD3, a large randomized controlled trial, compared
VTE prophylaxis for 12 days with rivaroxaban versus 12 days
enoxaparin following TKR. Rivaroxaban reduced total VTE
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